U.S. markets closed

Psychemedics Corporation (PMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
6.70+0.15 (+2.29%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close6.55
Open6.61
Bid6.35 x 900
Ask7.50 x 1000
Day's Range6.65 - 6.70
52 Week Range3.58 - 7.90
Volume3,436
Avg. Volume22,696
Market Cap37.094M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.58
Earnings DateAug 10, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateFeb 20, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Psychemedics Corporation Reports First Quarter 2021 Financial Results
    GlobeNewswire

    Psychemedics Corporation Reports First Quarter 2021 Financial Results

    ACTON, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2021. The Company’s revenue for the quarter ended March 31, 2021 was $5.7 million versus $7.5 million for the quarter ended March 31, 2020, a decrease of 24%. Net income for the quarter ended March 31, 2021 was $0.1 million or $0.01 per diluted share, versus net loss of $0.2 million or ($0.03) per diluted share, for the comparable period last year, an increase of $0.04 per diluted share. Raymond C. Kubacki, Chairman and Chief Executive Officer, stated: "We continued to see improvement in total revenues, month-to-month and quarter-to-quarter, since the COVID-19 shutdown hit full force in April last year. The driving force in the continuing improvement is the growth in our domestic business. While total revenues for this first quarter declined 24% vs. Q1 2020, domestic revenues declined a lesser 15% and March showed an increase in total revenues and domestic revenues vs. March 2020. International volumes, primarily Brazil, continued to be off significantly as anticipated and as mentioned in our Q4 press release and shareholder letter in our Annual Report. We will keep our options open, but our focus is on our domestic business. Our first quarter earnings were impacted primarily by two countervailing factors: 1) lower volume and revenues compared to Q1 2020 had a significant negative impact and 2) application of the Employee Retention Credit ("ERC") had a positive impact. The ERC is a refundable federal payroll tax credit for certain wages paid in 2021. Under the provisions of the CARES Act, we became entitled to a refundable federal employee retention tax credit subject to certain criteria. Accordingly, we recorded a $0.8 million employee retention tax credit during the three months ended March 31, 2021. We have already determined we are eligible for the employee retention tax credit in second quarter of 2021 and expect to be for the remainder of 2021. However, even excluding the ERC, we still had a strong gross margin performance, especially in view of the 24% reduction in total revenues. With the ERC credit and our cost reduction and controls initiatives (including a second round of salary cuts for management and high-level teammates on February 1 of this year), we were able to record a profit in Q1. We are pleased with how our first quarter progressed. I am proud of all of our teammates and their commitment to providing the highest quality services and accurate results, and the value add for our clients, during this difficult COVID-19 pandemic. With all the actions taken noted above, including strict cost controls, we believe we are well positioned, especially in our domestic business, to get back on the track of profitable growth as the country opens up and the economy recovers. As an update on our PPP Loan, in May 2020, the Company received loan proceeds of $2.2 million under the Paycheck Protection Program (“PPP”) administered by the U.S. Small Business Administration (“SBA”). These funds were fully used as of July 2020. On November 6, 2020, the Company submitted an application for forgiveness of the entire amount due on the loan. This application was approved by Bank of America and has now been sent to the SBA to review the request for forgiveness. The review with SBA is ongoing. The Company had approximately $2.2 million of cash and cash equivalents ($6.3 million of working capital) as of March 31, 2021. The total equipment financing outstanding was $1.8 million as of March 31, 2021, compared to a total amount borrowed of $12.2 million reflecting repayments of $10.4 million since May 2014. The PPP Loan outstanding was $2.2 million as of March 31, 2021. The Company believes the PPP Loan will be forgiven in 2021 for the total amount outstanding since we satisfied all eligibility criteria. The Company paid 94 consecutive dividends (23 ½ years) through the first quarter of 2020, even during the financial crisis in 2008. However, because of the current COVID-19 pandemic, the dividend was suspended during 2020 and first quarter 2021 as we prioritized our liquidity and balance sheet. We have consistently been committed to paying a dividend and it took a pandemic for us to break our long history of consecutive quarterly dividend payments. Our Board of Directors share our confidence in the future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we grow. We evaluate the dividend each quarter and will continue to do so as we move forward.” Psychemedics Corporation is the world’s largest provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods. Cautionary Statement for purposes of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, cash flows, receivables collection dates, dividends, future business, growth opportunities, profitability, pricing, new accounts, customer base, market share, test volume, customer anticipated testing volume following the COVID-19 pandemic, sales and marketing strategies, market demand for drug testing services in Brazil, U.S. and foreign drug testing laws and regulations, including, without limitation, Brazilian professional driver drug testing requirements, required investments in plant, equipment and people and new test development, the effect of COVID-19 on our business, including its effects on our business, and profitability, and on the well-being and availability of our employees, the continued operation of our testing facilities and loan forgiveness under the PPP program) may be “forward looking” statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the severity of the COVID-19 pandemic, and its impact on the Company’s markets, including its impact on the Company’s customers, suppliers and employees, as well as its risk on the United States and worldwide economies, the timing, scope and effectiveness of further governmental, regulatory, fiscal monetary and public health responses to the COVID-19 pandemic, Internal Revenue Service refund processing timeframes, compliance by the Company with repayment forgiveness requirements under the PPP, changes in U.S. and foreign government regulations, including but not limited to FDA regulations, changes in Brazilian laws and regulations and proposed laws and regulations and the implementation of such laws and regulations, currency risks, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, leveraging of its global operating platform, risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission. With respect to the continued payment of cash dividends, factors include, but are not limited to, all of the factors listed above with respect to the impact of the COVID-19 pandemic on our business generally, plus cash flows, available surplus, capital expenditure reserves required, debt service obligations, regulatory requirements, requirements under our bank loan agreements and other factors that the Board of Directors of the Company may take into account. The forward-looking statements contained herein speak only of the Company's expectations as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company's expectations or any change in events, conditions, or circumstances on which any such statement is based. The Psychemedics Corporation web site is www.psychemedics.com Andrew LimbekVice President, Controller (978) 206-8220AndrewL@psychemedics.com Psychemedics CorporationConsolidated Statements of Operations(in thousands, except per share amounts)(UNAUDITED) Three Months Ended March 31, 2021 2020 Revenues$5,713 $7,537 Cost of revenues 3,145 4,809 Gross profit 2,568 2,728 Operating Expenses: General & administrative 1,529 1,533 Marketing & selling 642 1,106 Research & development 280 331 Total Operating Expenses 2,451 2,970 Operating income (loss) 117 (242)Other expense (14) (73) Net income (loss) before provision for (benefit from) income taxes 103 (315) Provision for (benefit from) income taxes 20 (156) Net income (loss)$83 $(159) Diluted net income (loss) per share$0.01 $(0.03) Dividends declared per share$- $0.18 Psychemedics CorporationConsolidated Balance Sheets(in thousands, except par value)(UNAUDITED) March 31, December 31, 2021 2020 ASSETS Current Assets: Cash and cash equivalents$2,190 $2,833 Accounts receivable, net of allowance for doubtful accounts 4,020 3,356 Prepaid expenses and other current assets 1,898 914 Income tax receivable 2,519 2,495 Total Current Assets 10,627 9,598 Fixed assets, net of accumulated amortization and depreciation 8,616 9,231 Other assets 882 888 Operating lease right-of-use assets 4,255 4,286 Total Assets$24,380 $24,003 LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Accounts payable$1,109 $577 Accrued expenses 1,567 1,801 Current portion of long-term debt 691 688 Current portion of operating lease liabilities 963 875 Total Current Liabilities 4,330 3,941 Long-term debt 3,270 3,444 Deferred tax liabilities, long-term 211 211 Long-term portion of operating lease liabilities 3,757 3,895 Total Liabilities 11,568 11,491 Shareholders' Equity: Common stock, $0.005 par value; 50,000 shares authorized 6,205 shares issued at March 31, 2021 and December 31, 2020, respectively, and 5,537 shares outstanding at March 31, 2021 and December 31, 2020, respectively 31 31 Additional paid-in capital 33,020 32,803 Less - Treasury stock, at cost, 668 shares ( 10,082) ( 10,082) Accumulated deficit ( 8,523) ( 8,606) Accumulated other comprehensive loss ( 1,634) ( 1,634) Total Shareholders' Equity 12,812 12,512 Total Liabilities and Shareholders' Equity$24,380 $24,003

  • Psychemedics Corporation Reports Fourth Quarter and Full Year 2020 Financial Results
    GlobeNewswire

    Psychemedics Corporation Reports Fourth Quarter and Full Year 2020 Financial Results

    ACTON, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced fourth quarter and full year financial results for the period ended December 31, 2020. The Company's revenue for the year ended December 31, 2020 was $21.4 million versus $37.7 million for the twelve months ended December 31, 2019, a decrease of 43%. Net loss for the twelve months ended December 31, 2020 was $3.9 million or $0.70 per diluted share, versus net income of $1.5 million or $0.28 per diluted share, for the comparable period last year. The Company’s revenue for the quarter ended December 31, 2020 was $5.3 million versus $8.7 million for the quarter ended December 31, 2019, a decrease of 39%. Net loss for the quarter ended December 31, 2020 was $0.5 million or $0.10 per diluted share, versus $0.5 million or $0.09 per diluted share, for the comparable period last year. Raymond C. Kubacki, Chairman and Chief Executive Officer, stated: “To say 2020 was a year of great challenges is a total understatement. Our Company had weathered numerous recessions, including 2008-2009 (which was the worst recession since the Great Depression) and we still maintained our profitability every year since 1993. However, the Coronavirus pandemic (COVID-19) which brought on a basic lockdown in the U.S. and internationally for a large part of the year was a massive challenge of unprecedented proportion. As a result, the Company experienced significant declines in domestic and international testing and revenues. However, it is a testament to our broad and diverse client base that we were able to weather this storm. We had key segments like Oil & Gas and Trucking which, while impacted, still were anchors to windward against this storm. The good news is, declines in our domestic business recovered significantly throughout the third and fourth quarters as COVID-19 restrictions eased and the overall economy began an upturn. While we were not at our pre-COVID-19 levels, however, fourth quarter testing volumes increased compared to the third and second quarters of 2020 and the recovery of our base business has continued thus far. On the international front, I mentioned in last year’s fourth quarter press release and annual shareholder letter that the Brazil driver license market had become increasingly unattractive from a profitability viewpoint; and that we expected this business to continue to decline throughout the year 2020. The Brazil government lockdown of the economy for most of the year just accelerated this decline. However, as I also previously mentioned, any reduction in Brazil revenues will have a lesser impact on profits than the decline in domestic revenues. As of now, there is great uncertainty in the Brazil market. We will keep our options open as we move forward; but we are only interested in profitable growth. While COVID-19 has continued to affect the Company’s sales volumes, it has not impacted the Company’s ability to perform testing. The Company has had no interruptions to laboratory operations, which is a great testament to our outstanding lab team. And we have continued with safety measures to safeguard the well-being of our lab team, as well as maintaining business continuity. Beginning in the first quarter, we took steps to reduce our cost structure and continued as the year progressed (excluding the PPP Loan period). We implemented staff reductions, salary reductions and suspension of the Company’s 401(k) match program. Therefore, the decline in our earnings was primarily due to the decline in our testing volume and revenues. In May 2020, the Company received loan proceeds of $2.2 million under the Paycheck Protection Program (“PPP”) administered by the U.S. Small Business Administration (“SBA”). These funds were fully used as of July 2020. On November 6, 2020, the Company submitted an application for forgiveness of the entire amount due on the loan. Meanwhile, the full amount of the staffing expenses associated with this PPP Loan were recorded as both cost of revenues and operating expenses. While we believe we satisfied all eligibility criteria for the PPP Loan, and while the Company cannot provide assurance that the PPP Loan will be forgiven, had we been able to record as forgiveness income the $2.2 million related to PPP Loan, our loss of $3.9 million ($0.70 diluted EPS) for the year would have been $1.7 million ($0.30 diluted EPS); and our loss for the fourth quarter of $0.5 million ($0.10 diluted EPS) would instead have been net income of $1.6 million ($0.29 diluted EPS). As stated, we have applied for loan forgiveness. This application was approved by Bank of America and has now been sent to the SBA to review the request for forgiveness. Therefore, we believe these reported results do not reflect the real underlying strength of the Company. We look for continuing improvement as the country continues to open up. Companies and our clients continue to give us feedback that they need to be even more vigilant than ever to try to keep drug abusers out of the workplace given the long shut-down of the country. Therefore, we believe we are well positioned, especially in our domestic business, as the economy recovers. The Company’s balance sheet remains strong with $2.8 million of cash and cash equivalents ($5.7 million of working capital) at year end. The total equipment financing outstanding was $2.0 million as of December 31, 2020, compared to a total amount borrowed of $12.2 million reflecting repayments of $10.2 million since May 2014. The PPP Loan outstanding was $2.2 million as of December 31, 2020. The Company believes the PPP Loan will be forgiven in 2021 for the total amount outstanding since we satisfied all eligibility criteria. The Company paid 94 consecutive dividends (23 ½ years) through the first quarter of 2020, even during the financial crisis in 2008. However, because of the current COVID-19 pandemic, the dividend was suspended during 2020 as we prioritized our liquidity and balance sheet. We have consistently been committed to paying a dividend and it took a pandemic for us to break our long history of consecutive quarterly dividend payments. Our Board of Directors share our confidence in the future of Psychemedics and remain committed to rewarding shareholders and sharing the financial success of the Company with them as we grow. We evaluate the dividend each quarter and will continue to do so as we move forward.” Psychemedics Corporation is the world’s largest provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods. Cautionary Statement for purposes of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, cash flows, receivables collection dates, dividends, future business, growth opportunities, profitability, pricing, new accounts, customer base, market share, test volume, customer anticipated testing volume following the COVID-19 pandemic, sales and marketing strategies, market demand for drug testing services in Brazil, U.S. and foreign drug testing laws and regulations, including, without limitation, Brazilian professional driver drug testing requirements, required investments in plant, equipment and people and new test development, the effect of COVID-19 on our business, including its effects on our business, and profitability, and on the well-being and availability of our employees, the continued operation of our testing facilities and loan forgiveness under the PPP program) may be “forward looking” statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the severity of the COVID-19 pandemic, and its impact on the Company’s markets, including its impact on the Company’s customers, suppliers and employees, as well as its risk on the United States and worldwide economies, the timing, scope and effectiveness of further governmental, regulatory, fiscal monetary and public health responses to the COVID-19 pandemic, Internal Revenue Service refund processing timeframes, compliance by the Company with repayment forgiveness requirements under the PPP, changes in U.S. and foreign government regulations, including but not limited to FDA regulations, changes in Brazilian laws and regulations and proposed laws and regulations and the implementation of such laws and regulations, currency risks, R&D spending, competition (including, without limitation, competition from other companies pursuing the same growth opportunities), the Company’s ability to maintain its reputation and brand image, the ability of the Company to achieve its business plans, cost controls, leveraging of its global operating platform, risks of information technology system failures and data security breaches, the uncertain global economy, the Company’s ability to attract, develop and retain executives and other qualified employees and independent contractors, including distributors, the Company’s ability to obtain and protect intellectual property rights, litigation risks, general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission. With respect to the continued payment of cash dividends, factors include, but are not limited to, all of the factors listed above with respect to the impact of the COVID-19 pandemic on our business generally, plus cash flows, available surplus, capital expenditure reserves required, debt service obligations, regulatory requirements, requirements under our bank loan agreements and other factors that the Board of Directors of the Company may take into account. The forward-looking statements contained herein speak only of the Company's expectations as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in the Company's expectations or any change in events, conditions, or circumstances on which any such statement is based. The Psychemedics Corporation web site is www.psychemedics.com Andrew LimbekVice President, Controller (978) 206-8220AndrewL@psychemedics.com Psychemedics CorporationConsolidated Statements of Operations(in thousands, except per share amounts)(UNAUDITED) Three Months Ended Year Ended December 31, December 31, 2020 2019 2020 2019 Revenues$5,335 $8,715 $21,360 $37,678 Cost of revenues 4,058 5,230 16,474 21,234 Gross profit 1,277 3,485 4,886 16,444 Operating Expenses: General & administrative 1,368 2,534 6,095 7,221 Marketing & selling 719 1,203 3,577 4,658 Research & development 299 354 1,280 1,567 Total Operating Expenses 2,386 4,091 10,952 13,446 Operating (loss) income (1,109) (606) (6,066) 2,998 Other (loss) income (11) 4 (140) 58 Net (loss) income before provision for income taxes (1,120) (602) (6,206) 3,056 (Benefit from) provision for income taxes (577) (72) (2,347) 1,514 Net (loss) income$(543) $(530) $(3,859) $1,542 Diluted net (loss) income per share$(0.10) $(0.09) $(0.70) $0.28 Dividends declared per share$- $0.18 $0.18 $0.72 Psychemedics CorporationConsolidated Balance Sheets(in thousands, except par value)(UNAUDITED) December 31, December 31, 2020 2019ASSETS Current Assets: Cash and cash equivalents$2,833 $7,283 Accounts receivable, net of allowance for doubtful accounts 3,356 3,780 Prepaid expenses and other current assets 914 1,788 Income tax receivable 2,495 - Total Current Assets 9,598 12,851 Fixed assets, net of accumulated amortization and depreciation 9,231 10,862 Other assets 888 943 Operating lease right-of-use assets 4,286 2,875 Total Assets$24,003 $27,531 LIABILITIES AND SHAREHOLDERS' EQUITY Current Liabilities: Accounts payable$577 $617 Accrued expenses 1,801 3,577 Current portion of long-term debt 688 678 Current portion of operating lease liabilities 875 963 Total Current Liabilities 3,941 5,835 Long-term debt 3,444 1,951 Deferred tax liabilities, long-term 211 550 Long-term portion of operating lease liabilities 3,895 2,375 Total Liabilities 11,491 10,711 Shareholders' Equity: Common stock, $0.005 par value; 50,000 shares authorized 6,205 shares and 6,185 shares issued at December 31, 2020 and 2019, respectively, 5,537 shares outstanding and 5,517 shares outstanding at December 31, 2020 and 2019, respectively 31 31 Additional paid-in capital 32,803 32,249 Less - Treasury stock, at cost, 668 shares (10,082) (10,082)Accumulated deficit (8,606) (3,754)Accumulated other comprehensive loss (1,634) (1,624)Total Shareholders' Equity 12,512 16,820 Total Liabilities and Shareholders' Equity$24,003 $27,531

  • Robyn C. Davis Joins Psychemedics Board of Directors
    GlobeNewswire

    Robyn C. Davis Joins Psychemedics Board of Directors

    ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately. Ms. Davis will be filling the vacancy created by the untimely passing this past December of Clint Allen, a long- time and dedicated Psychemedics board member. Ray Kubacki, Chairman and CEO stated “We are excited to have Robyn join our board. She brings a wealth of experience and a balanced perspective in a number of areas particularly in life sciences and strategy that will prove most helpful to Psychemedics growth as we move forward.” Ms. Davis currently serves as a corporate Director for Brooks Automation (BRKS), a $900 million revenue global leader in robotics serving the semiconductor and life sciences markets. She has served on the Audit, Compensation and Finance committees. Additionally, Robyn serves as a Director for Akston Bioscience, an early- stage specialty pharmaceutical company that develops novel biologic therapeutics for diabetes and vaccines. Ms, Davis is also a Managing Director of Angel Healthcare Investors where she has managed early-stage investments in medical devices, life sciences, information technology and professional services over the past 20 years. Throughout her career, Ms. Davis has advised governments, boards, CEO’s, and senior executives on value-creation, growth strategy, cost reduction, and leadership development. She has worked as an independent advisor as well as a Consultant at Bain & Co. and a Director at Barents, LLC. Ms. Davis holds an Executive Masters Professional Director Certification from the American College of Corporate Directors and was also recognized by Women, Inc. magazine as a “Most Influential Corporate Director” in 2019. She is a graduate of Tufts University and Harvard Business School. Psychemedics Corporation is the world’s largest provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods. The Psychemedics web site is www.psychemedics.com. Contact: Raymond C. Kubacki, Chairman, President and CEOPhone: (978) 206-8220